Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Pioglitazone hydrochloride
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Pioglitazone Hydrochloride
• Name: Pioglitazone Hydrochloride Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 112529-15-4
• Mf: C19h21cln2o3s
• MW: 392.9
• Melting Point: 193-194 C
• Density: 1.26 g/cm3
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone hydrochloride

Product Description

Product Details

Product name	Pioglitazone
Cas number	112529-15-4
Apperance	White Powder
Density	1.26 g/cm3
MF	C19H21ClN2O3S
Melting point	193-194ºC
MW	392.90000

Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of  dependent diabetes mellitus (NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester into thiazolidine. As with other representatives in this class, it potently activates the nuclear receptor peroxisome proliferator-activated receptor gamma which is believed to be involved in the regulation of  resistance and adipogenesis. In several obese and obese diabetic animal models, treatment with Pioglitazone resulted in reductions in plasma glucose and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs , was shown to significantly improve glycemic control in type-2 diabetes and demonstrated a beneficial effect on  resistance and other clinically relevant parameters as plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be safe and well tolerated and is said to have a lower occurrence of hepatic toxicity as well as a low probability for drug interaction.

Application&Function

Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin.The main study that looked at the medication, however, found no statistically significant difference in the main cardiovascular outcomes that were looked at.
The secondary outcome of death from all causes, myocardial infarction, and stroke were lower. Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.

Specification